核苷类似物治疗失代偿期乙型肝炎肝硬化临床分析被引量：2

导出

摘要目的通过核苷类似物治疗乙型肝炎肝硬化失代偿期患者,对比观察临床疗效。方法在病人知情同意情况下随机分组,进行核苷类似物抗病毒治疗,并设立常规护肝治疗组。结果抗病毒治疗1年,拉米夫定治疗患者HBV DNA全部转阴,HBeAg血清转换率为26%,肝功能明显好转,疗效显著;阿德福韦酯组疗效相对较慢,只出现3例HBV DNA转阴,HBeAg血清转换率为13%,两组无1例患者死亡;未抗病毒组疗效最差,2例死亡,3组疗效差异性显著(P<0.05)。结论乙型肝炎肝硬化失代偿期患者应进行抗病毒治疗,并应首先选用起效快的拉米夫定迅速控制病情。

作者汤茂刚张兆勤

机构地区江苏省沭阳县人民医院感染病科

出处《实用肝脏病杂志》 CAS 2008年第5期326-327,共2页 Journal of Practical Hepatology

关键词失代偿期乙型肝炎肝硬化拉米夫定阿德福韦酯

分类号 R512.62 [医药卫生—内科学] R575.2 [医药卫生—消化系统]

引文网络
相关文献

参考文献5

1曹继红,徐焕新.拉米夫定治疗失代偿期乙型肝炎肝硬化患者疗效观察[J].实用肝脏病杂志,2007,10(2):116-117. 被引量：4
2中华医学会传染病与,寄生虫病学分会,肝病学分会.病毒性肝炎防治方案[J].中华肝脏病杂志,2000,8(6):324-329. 被引量：14016
3拉米夫定临床应用专家组 ,万谟彬.2004年拉米夫定临床应用专家共识[J].中华肝脏病杂志,2004,12(7):425-428. 被引量：257
4蔡伟,谢青.核苷类药物治疗慢性乙型肝炎的研究进展[J].国外医学（流行病学．传染病学分册）,2005,32(1):34-37. 被引量：15
5曾维群,郭树华,张大志,周智,任红,张全海,王志毅.拉米夫定治疗活动性肝炎肝硬化的疗效观察[J].中华肝脏病杂志,2003,11(3):176-178. 被引量：42

二级参考文献48

1万谟彬.特殊慢性乙型肝炎患者中核苷类似物的应用[J].中华传染病杂志,2005,23(S1):29-33. 被引量：15
2Peters MG, Hann HW, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lmalivudine-reslstant chronic hepatitis B. Gastroenterology, 2004,126( 1 ) : 343-347.
3Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre-and post-liver transplantation patients. Hepatology, 2003,38 (6) : 1419-1427.
4Leung N, Gish RG, Wang C, et al. A randomized, double-blind compari-son of 3 doses of emtricitabine in patients with chronic hepatitis B given 48 weeks of treatment. Hepatology, 2001,34 : .349A.
5Gish R, Leung N, Wang C, et al. Antiviral activity, safety, and incidence of resistance in chronically infected hepatitis B patients ( CHB ) given once daily emtricitabine for 2 years. Hepatology,2002,36( Suppl ) :A838.
6van Bommel F, Wunsche T, Schurmmm D, et al. A comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus(HBV) infection. Hepatology, 2003,38 ( Sutppl 1 ) : 275A.
7Nelson M, Portsmouth S, Stebbing J, et al .An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS,2003,17(1) :F7-10.
8Lai CL, Rosmawati M, Lao J, et al. Entetecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology, 2002, 123 (6) : 1831 - 1838.
9Chang TF, Hadzlyannis S, Cianciara J, et al. Sustained viral load and .ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine. Hepatology, 2002, 36(Suppl) : 2,550.
10Tenney D J, kevine SM, Rose RE., et al. Clinical ernergence of enteeavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother, 2004, 48 ( 9 ) :3498 -3507.